Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models.

Most chemotherapy regimens rely on systemic administration of drugs leading to a wide array of toxicities. Using viral-vector-mediated gene modification of muscle tissues, we have developed a method for gene-directed enzyme prodrug therapy that allows for localized drug administration. An inactive prodrug of geldanamycin was activated locally for inhibition of tumor growth without systemic toxicities.

Fat grafting as a vehicle for the delivery of recombinant adenoassociated viral vectors to achieve gene modification of muscle flaps.

Background: The combination of gene therapy and plastic surgery may have the potential to improve the specificity that is needed to achieve clinically applicable treatment regimens. Our goal was to develop a method for gene modification that would yield sustainable production of gene products but would be less time consuming than existing protocols.

Methods: An adenoassociated virus was used to deliver gene products to pectoralis muscle flaps.

c-Jun promotes neurite outgrowth and survival in PC12 cells.

We investigated the function of c-Jun in PC12 cells by transfecting them with a plasmid containing a c-Jun cDNA transcription cassette. Transfected cells expressed high levels of c-Jun mRNA and protein and demonstrated an increase in both AP-1 DNA binding and gene activation. The c-Jun over-expressing cells showed marked neurite outgrowth but no evidence of spontaneous cell death.

CREB phosphorylation promotes nerve cell survival.

The cyclic AMP-responsive element binding protein (CREB) is a posttranslationally activated transcription factor that has been implicated in numerous brain functions including cell survival. In this study we investigated whether CREB overexpression using transient transfection of a pAAV/CMV-CREB plasmid altered neuronal cells' susceptibility to apoptosis. We found that elevated CREB protein inhibited apoptosis induced by okadaic acid.